AK112 plus chemo for first-line metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to other parts of the body (metastatic) and you have not had chemotherapy for it yet.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are able to do most of your daily activities on your own (ECOG 0 or 1).
- Your organ function (like liver, kidney, and blood counts) is good enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests a new combination of drugs (Ivosidenib/AK112, CapeOX chemotherapy, and radiation) for people with advanced colorectal cancer that has spread and cannot be removed with surgery. It is for those whose tumors are MSS (microsatellite stable) type and who have not received recent chemotherapy.
This trial tests whether combining short-course radiation with an immune therapy drug (AK112) plus chemotherapy before surgery is better than radiation alone for locally advanced rectal cancer. It aims to shrink tumors and improve outcomes without needing stronger treatments later.
This trial tests a combination of two study drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments. It aims to see if the combination can help shrink tumors.
Hear when a new Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.